Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 3, 2023

Investigational Drug Information for Semaxanib

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the development status for investigational drug Semaxanib?

Semaxanib is an investigational drug.

There have been 27 clinical trials for Semaxanib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1^st 1999.

The most common disease conditions in clinical trials are Sarcoma, Colorectal Neoplasms, and Sarcoma, Kaposi. The leading clinical trial sponsors are National Cancer Institute (NCI), Case Comprehensive Cancer Center, and Jonsson Comprehensive Cancer Center.

Summary for Semaxanib

US Patents	0
International Patents	0
US Patent Applications	5,673
WIPO Patent Applications	0
Japanese Patent Applications	1,096
Clinical Trial Progress	Phase 3 (1999-11-01)
Vendors	75

Recent Clinical Trials for Semaxanib

Title	Sponsor	Phase
Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma	National Cancer Institute (NCI)	Phase 1/Phase 2
Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma	Radiation Therapy Oncology Group	Phase 1/Phase 2
Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma	National Cancer Institute (NCI)	Phase 1/Phase 2

See all Semaxanib clinical trials

Clinical Trial Summary for Semaxanib

Top disease conditions for Semaxanib

Top clinical trial sponsors for Semaxanib

See all Semaxanib clinical trials

US Patents for Semaxanib

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Mallinckrodt

McKesson

Merck

Moodys

McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.